Company Overview
DNA X, Inc. provides cryptocurrency trading services worldwide. The company operates a cryptocurrency trading platform that allows users to trade and swap cryptocurrencies for other cryptocurrencies or cash-equivalent currencies. It markets its services through word of mouth and earned media on social media platforms. The company serves individual cryptocurrency traders. The company was formerly known as Sonim Technologies, Inc. and changed its name to DNA X, Inc. in January 2026. DNA X, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Why Investors Should Care
Return on capital employed stands at 130.9%.
Operating margin of 54.2% supports profitability.
Recent Developments
- Trailing 12 Months Year-on-year growth — earnings +255.0%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 255.00% |
Stock Price Performance
| 1 Year: | -68.95% |
| 6 Months: | -28.38% |
| 3 Months: | -37.52% |
| 1 Month: | -17.20% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.72 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 130.9%.
CONS
- Trading 81.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Financial Services).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SONM DNA X, Inc. FINANCIAL | 3.13 | -0.38 | $4.66M | 0.00% | 130.93% | - | - | - |
| 2 | JPM JPMorgan Chase & Co. SPXR3KFINANCIAL | 353.51 | 15.15 | $939.70B | 1.72% | - | 17.79% | 12.50% | 14.83% |
| 3 | BRK-B Berkshire Hathaway Inc. SPXFINANCIAL | 505.83 | 12.72 | $712.23B | 0.00% | - | 12.12% | 4.18% | 9.44% |
| 4 | V Visa Inc. SPXR3KFINANCIAL | 368.64 | 31.35 | $628.20B | 0.72% | 37.15% | 61.19% | 14.33% | 13.04% |
| 5 | MA Mastercard Incorporated SPXR3KFINANCIAL | 570.89 | 31.44 | $496.37B | 0.62% | 60.19% | - | 12.29% | 19.21% |
| 6 | BAC Bank of America Corporation SPXR3KFINANCIAL | 62.39 | 14.41 | $436.28B | 2.04% | - | 11.20% | 3.14% | 4.27% |
| 7 | BRK-A Berkshire Hathaway Inc. FINANCIAL | 757,791.00 | 12.71 | $370.14B | 0.00% | - | 12.12% | 7.60% | 10.02% |
| 8 | HSBC HSBC Holdings plc FINANCIAL | 106.26 | 15.18 | $363.70B | 3.65% | - | 13.10% | 9.75% | 12.72% |
| 9 | MS Morgan Stanley SPXR3KFINANCIAL | 216.24 | 17.48 | $339.62B | 2.26% | - | 17.97% | 3.76% | 9.66% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 26.48M | 43.75M | 28.85M | 12.71M | 21.06M | 14.39M | 12.24M | 11.95M | 14.45M | 13.26M | 11.96M | 20.50M | 25.80M | 26.84M | 27.57M | 9.12M | 11.52M | 15.02M | - | 0 | 11.19M | 16.21M | -44.12M | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.17M | 8.37M | 10.35M | 14.40M | -33.11M | - |
| Gross Profit | 5.26M | 10.54M | 14.06M | 9.02M | 14.45M | 6.88M | 2.17M | 4.92M | 4.40M | 2.46M | 2.65M | 1.78M | 1.53M | 2.85M | 3.32M | 4.17M | 4.43M | 5.60M | 2.90M | 2.97M | 4.23M | -183.00K | 8.36M | 845.00K | 1.82M | -11.02M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 870.00K | 7.58M | 5.80M | -15.68M | 3.62M |
| Operating Income | -4.01M | 596.00K | 3.28M | -4.14M | -4.58M | -6.26M | -9.06M | -6.62M | -6.12M | -9.05M | -6.49M | -10.72M | -7.08M | -4.22M | -1.93M | 333.00K | 747.00K | 688.00K | -2.69M | -6.47M | -2.38M | - | -870.00K | -6.73M | -3.98M | 4.66M | -3.62M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 185.00K | -6.15M | -3.19M | 5.43M | -3.80M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 91.00K | 389.00K | 522.00K | 484.00K | 131.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -961.00K | -7.34M | -4.66M | 3.45M | -3.93M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 139.00K | 90.00K | -361.00K | 0 |
| Net Income | -5.07M | -123.00K | 2.13M | -5.12M | -5.60M | -6.78M | -9.96M | -7.10M | -6.46M | -9.28M | -6.69M | -10.94M | -7.21M | -4.22M | -1.61M | 227.00K | 509.00K | 527.00K | -2.91M | -6.62M | -2.51M | - | 458.00K | -7.47M | -4.75M | -8.89M | 6.34M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -1.40 | - | - | -0.38 | -0.22 | -0.04 | 0.01 | 0.11 | 0.12 | -0.65 | -1.41 | -9.32 | - | 1.41 | -0.79 | -4.83 | - | 5.01 |
| R&D Expense | 5.14M | 5.62M | 6.00M | 6.96M | 7.38M | 6.65M | 3.94M | 3.26M | 3.39M | 4.66M | 3.67M | 5.49M | 4.17M | 2.72M | -135.00K | 105.00K | - | 741.00K | 456.00K | 557.00K | 715.00K | - | 1.63M | 909.00K | 181.00K | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 135.66M | 116.25M | 63.99M | - | 69.83M | 93.63M | 0 | 0 |
| Cost of Revenue | - | - | - | - | 58.20M | 74.31M | 0 | 0 |
| Gross Profit | 48.09M | 34.51M | 15.21M | - | 11.62M | 19.32M | 0 | 0 |
| Operating Expenses | - | - | - | - | 25.91M | 18.81M | 3.10M | 5.41M |
| Operating Income | 5.39M | -22.38M | -29.26M | - | -14.29M | 513.00K | -3.10M | -5.41M |
| EBITDA | - | - | - | - | -11.43M | 2.50M | 703.00K | -2.17M |
| Interest Expense | - | - | - | - | 97.00K | 15.00K | 29.00K | 1.49M |
| Pretax Income | - | - | - | - | -13.90M | 284.00K | -2.88M | -7.96M |
| Tax Provision | - | - | - | - | 184.00K | 374.00K | 0 | 0 |
| Net Income | 1.28M | -25.83M | -29.93M | - | -14.09M | -90.00K | -33.65M | -20.66M |
| Diluted EPS | - | - | - | - | -4.90 | -0.36 | -128.37 | -28.58 |
| R&D Expense | 23.25M | 26.06M | 16.22M | 17.70M | 7.97M | 1.77M | 14.23M | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 67.34M | 55.46M | 50.31M | - | 53.69M | 56.04M | 39.74M | 43.90M |
| Current Assets | - | - | - | - | - | 43.63M | 43.79M | 32.16M | 28.91M |
| Cash & Equivalents | - | 13.05M | 11.30M | 22.14M | - | 13.21M | 9.40M | 5.34M | 1.30M |
| Inventory | - | - | - | - | 5.54M | 3.91M | 6.52M | 10.62M | - |
| Receivables | - | - | - | - | 10.80M | 22.43M | 25.30M | 4.34M | - |
| Total Liabilities | - | 62.22M | 29.93M | 21.90M | - | 33.64M | 33.67M | 45.44M | 50.62M |
| Current Liabilities | - | 48.20M | 27.61M | 20.47M | - | 32.06M | 32.15M | 43.74M | 48.03M |
| Long Term Debt | - | 13.21M | 362.00K | 185.00K | 66.00K | - | - | - | - |
| Total Debt | - | - | - | - | 214.00K | 213.00K | 55.00K | - | 5.07M |
| Total Equity | -89.91M | 5.13M | 25.52M | 28.41M | - | 20.05M | 22.37M | -5.70M | -6.73M |
| Shares Outstanding | - | - | - | - | - | 4.08M | 4.31M | 4.98M | 1.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 3.86M | -33.52M | -10.56M | - | -12.36M | -4.05M | -8.49M | -23.53M |
| Investing Cash Flow | -2.54M | -1.36M | -11.00K | - | -8.00K | -36.00K | -214.00K | 0 |
| Financing Cash Flow | 10.15M | 33.13M | 21.41M | - | 14.35M | 272.00K | 4.65M | 19.49M |
| Capital Expenditure | -787.00K | -992.00K | -11.00K | -46.00K | -8.00K | -36.00K | -214.00K | - |
| Free Cash Flow | 3.07M | -34.52M | -10.57M | - | -12.37M | -4.09M | -8.70M | -23.53M |
| Net Change in Cash | - | - | - | - | 1.98M | -3.82M | -4.05M | -4.04M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 35.4% | 29.7% | 23.8% | - | 16.6% | 20.6% | - | - |
| Operating Margin % | 4.0% | -19.3% | -45.7% | - | -20.5% | 0.5% | - | - |
| Net Margin % | 0.9% | -22.2% | -46.8% | - | -20.2% | -0.1% | - | - |
| ROE % | 24.9% | -101.2% | -105.4% | - | -70.3% | -0.4% | 590.3% | 307.1% |
| ROCE % | 28.2% | -80.4% | -98.1% | - | -66.1% | 2.1% | 77.5% | 130.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | C2c Wealth Management, LLC | 2.39% | 35.50K | $122.83K |
| 2 | Blackrock Inc. | 0.94% | 14.01K | $48.46K |
| 3 | Citadel Advisors Llc | 0.86% | 12.74K | $44.08K |
| 4 | Geode Capital Management, LLC | 0.85% | 12.58K | $43.54K |
| 5 | Vanguard Capital Management LLC | 0.40% | 5.90K | $20.42K |
| 6 | Vanguard Fiduciary Trust Co | 0.30% | 4.50K | $15.56K |
| 7 | UBS Group AG | 0.15% | 2.30K | $7.97K |
| 8 | Tower Research Capital LLC (TRC) | 0.04% | 642 | $2.22K |
| 9 | SBI Securities Co., Ltd. | 0.01% | 214 | $740 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SONM
Sonim Technologies Maintains Nasdaq Compliance Amid Monitoring Period - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOaWxYeEpDd1h4cEQzQUlPbElCS1I3eDVjZjJzZmRXalE0Wl9QYTZhQ19vSVpDV25xZ1BWWHA5Mi1KTjZFRFF3aEZqa3E5M0pvS1lHUXUwZ0FBenBLWEY3R1U5SVc5eVByOFg4eDJOT1lXYl9yUm8yRkIxVlZxeEVvemh2aVMxRTZoemtrbG…
DNA X (SONM) turns to cash after equity plan runs out of shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOZHp6TjVTZHlsMTJhY0JJUkY3Nk5EMXU5dmNXS0FuSEhJLVdOZEZVdy12VUVIdVdHOWZacWE1LUFmUExhQnBUY2ZWR3FGUmdSeXZXR2dYczlOZlg0QWpRbFk5SVBHbGxSVm1YSmQ3eU1MUVJnaWxsZGtUTVZKdmVUcmJPSHI1VTRQTm1lR2…
Sonim Technologies Inc (NASDAQ: SONM) Share Price, SONM Stock News, SONM Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE81Z28xdjYzY3Q0dGc1dlVnb05pOGxuUzdNTEZBc19YNlJNMllkTUdkUjc2ZnZDS0N2UUpfdDBPdmpPOGhIN0FzNksxOHhFbE01MWpzRTl3?oc=5" target="_blank">Sonim Technologies Inc (NASDAQ: SONM) Share Price, …
DNA X: Q2 Earnings Snapshot - ktvb.com
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNTUxjeklmWXU1aW1rb3VBNkFrQU5LMWdtVnQ5U1Q3d3ZXbkh3aTk4SnNiWnRON1V6aWxUbVVONnJHY2F1UkcxNFI4NFowTEVHR1NCalJWRGV3QWVxQlhXa2tFUnZoOXE4am92RDZjb29BN1NtOVZDNEZPTWl5SF9UcXc2RzNwZnMxRlIweE…
SONM - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9tVzQzb08zT2R0MHEySmNnaTloQk9mVy1IdjBHUUdGM2R5TV83d1BpMHd4TktLaExBa25LRW15bDN0Vy1DVFE?oc=5" target="_blank">SONM</a> <font color="#6f6f6f">Finviz</font>…
DNA awards Substitute Cash Grants to board including CEO Mike Mulica - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOc0tEc1BObU5YX3drcmc1bWJmOFM3NVRhQ3RNb1AycTA1VkhjWnE1ZHpPSk9BeEUyLVdQcExsUUh1bThiLUpwUVpyY0V4c1ZXRFdFRFFrZk5lTVV0RmJMSGU2YVpyeHRXYjdBc3pLbHJfdzFEaVM5VS1qTVk0d2xBMEtwR0pSaTFON3NLOF…
SONM — Frequently Asked Questions
What is the current share price of DNA X, Inc. (SONM)?
As of 2026-09-19 21:16 PDT, DNA X, Inc. (SONM) trades at $3.13 on NasdaqCM. Its 52-week range is $2.75 to $16.87.
What is the market capitalisation of SONM?
DNA X, Inc. (SONM) has a market capitalisation of $4.66M on NasdaqCM.
What is the P/E ratio of SONM?
SONM trades at a trailing price-to-earnings (P/E) ratio of -0.38. The industry average P/E is 12.89. Its price-to-book (P/B) ratio is -4.18.
Is SONM a good stock to buy?
This page provides a data-driven analysis of DNA X, Inc. (SONM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.